TaiMed Biologics

4147 · TWO · Healthcare / Biotechnology

64.30TWD+2.30 (+3.71%)

Price History

Full chart

Market Stats

Previous Close62.00

Open63.00

Day Range62.30 – 64.50

52-Week Range47.00 – 76.80

Volume1.42M

Market Cap16.62B

P/E (TTM)0.00

Forward P/E1111.11

EPS-0.50

Dividend Yield0.00%

Beta-0.14

50-Day Avg61.97

200-Day Avg57.48

About

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Chin-Ming Chang Ph.D.
Employees0
HeadquartersNO. 607, Ruiguang Rd., Taipei, Taiwan, 11492, Taiwan
Websitehttps://www.taimedbiologics.com

Leadership

Mr. Chin-Ming Chang Ph.D.President, CEO & Representative Director
Dr. David D. Ho M.D.Co-Founder & Chief Scientific Advisor · b. 1953
Dr. Ing-Wen Tsai Ph.D.Co-Founder
Dr. Lan-Bo Chen Ph.D.Co-Founder
Chen YichengAccounting Supervisor

Financials

Income Statement

Currency: TWD	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	137.00K	319.00K	135.00K	-	-	-	-	2.08M	8.44M	241.04M	704.50M	722.49M	413.44M	563.01M	491.78M	610.16M	611.35M
Growth (%)	-	+132.85%	-57.68%	-	-	-	-	-	+306.36%	+2757.29%	+192.28%	+2.55%	-42.78%	+36.18%	-12.65%	+24.07%	+0.19%
Cost of Revenue	-	-	-	-	-	-	-	-	-	260.90M	474.49M	401.24M	329.49M	347.30M	266.54M	398.94M	351.90M
Gross Profit	-	-	-	-	-	-	-	2.08M	8.44M	-19.86M	230.01M	321.24M	83.95M	215.71M	225.23M	211.22M	259.45M
Gross Margin	-	-	-	-	-	-	-	100.00%	100.00%	-8.24%	32.65%	44.46%	20.31%	38.31%	45.80%	34.62%	42.44%
Operating Expense	-	-	-	-	-	-	-	314.97M	553.65M	300.93M	620.00M	454.00M	570.32M	407.57M	391.46M	463.49M	454.10M
Operating Income	-	-	-	-	-	-	-491.14M	-312.90M	-545.22M	-320.79M	-389.99M	-132.76M	-486.37M	-191.86M	-166.23M	-252.27M	-194.65M
Operating Margin	-	-	-	-	-	-	-	-15072.16%	-6462.97%	-133.08%	-55.36%	-18.38%	-117.64%	-34.08%	-33.80%	-41.34%	-31.84%
EBITDA	-	-	-	-	-	-	-	-	-541.43M	-257.88M	-485.76M	-39.43M	-306.83M	-102.74M	-24.61M	-34.95M	-3.45M
EBITDA Margin	-	-	-	-	-	-	-	-	-6418.09%	-106.98%	-68.95%	-5.46%	-74.21%	-18.25%	-5.00%	-5.73%	-0.56%
Net Income	-	-	-	-	-	-	-471.68M	-281.96M	-524.55M	-321.71M	-578.65M	-183.30M	-470.93M	-269.29M	-194.81M	-201.83M	-167.78M
Net Income Margin	-	-	-	-	-	-	-	-13581.98%	-6218.04%	-133.47%	-82.14%	-25.37%	-113.91%	-47.83%	-39.61%	-33.08%	-27.44%
R&D	206.91M	13.62M	222.56M	224.45M	233.05M	249.83M	442.46M	276.61M	510.74M	440.39M	575.83M	394.45M	460.60M	333.12M	294.28M	388.21M	381.84M
R&D as % of Total Revenue	151027.01%	4268.97%	164859.26%	-	-	-	-	13324.13%	6054.26%	182.70%	81.74%	54.60%	111.41%	59.17%	59.84%	63.62%	62.46%
Interest Expense	0	0	0	0	0	0	0	0	0	0	356.00K	4.09M	7.44M	10.10M	14.81M	12.60M	10.71M
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	-	-	-	-	0.00%	0.00%	0.00%	0.05%	0.57%	1.80%	1.79%	3.01%	2.07%	1.75%

Balance Sheet

Currency: TWD	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	617.22M	1.06B	854.39M	659.45M	714.72M	1.88B	4.93B	4.80B	4.50B	4.79B	4.73B	5.20B	4.61B	4.10B	3.89B	5.00B	4.81B
Total Liabilities	19.08M	16.88M	15.15M	14.23M	56.99M	50.35M	26.63M	87.99M	210.71M	710.55M	1.14B	1.78B	1.67B	1.39B	1.33B	976.34M	953.05M
Total Equity	598.14M	1.04B	839.24M	645.21M	657.73M	1.83B	4.90B	4.71B	4.29B	4.08B	3.59B	3.42B	2.94B	2.71B	2.57B	4.02B	3.86B
Cash	270.13M	763.50M	624.33M	509.27M	68.63M	407.46M	1.86B	1.99B	1.70B	586.09M	352.93M	572.09M	551.62M	274.11M	251.01M	580.23M	898.38M
Net Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	461.89M	471.00M	-	-

Cash Flow

Currency: TWD	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-	-	-	-	-	-	-446.26M	-172.29M	-516.48M	-522.86M	-655.31M	-201.94M	-211.28M	-605.21M	-25.60M	-379.55M	191.14M
Investing Cash Flow	-	-	-	-	154.51M	-	-1.59B	243.37M	212.14M	-684.25M	366.71M	-109.16M	190.92M	106.11M	-	-	-
Financing Cash Flow	-	690.00M	-	7.05M	4.07M	1.40B	3.48B	60.01M	18.92M	93.53M	57.92M	536.03M	2.79M	208.38M	-	-	-
Capital Expenditure	1.18M	981.00K	192.00K	2.10M	2.05M	15.11M	3.21M	9.98M	278.11M	846.38M	121.54M	53.61M	9.69M	3.56M	6.15M	19.35M	22.77M
Free Cash Flow	-	-	-	-	-	-	-	-	-798.38M	-1.71B	-793.14M	-586.46M	-224.84M	-609.97M	-31.75M	-398.90M	168.38M
FCF to OCF	-	-	-	-	-	-	-	-	154.58%	326.67%	121.03%	290.42%	106.42%	100.79%	124.03%	105.10%	88.09%

Earnings

Report Date	Mar 14, 2016	Apr 28, 2016	Aug 14, 2016	Nov 11, 2016	Mar 6, 2017	Apr 28, 2017	Aug 11, 2017	Nov 14, 2017	Mar 30, 2018	Apr 30, 2018	Aug 14, 2018	Nov 14, 2018	Mar 15, 2019	May 14, 2019	Aug 11, 2019	Nov 7, 2019	Mar 13, 2020	Apr 23, 2020	Aug 12, 2020	Nov 10, 2020	May 13, 2021	Aug 12, 2021	Nov 13, 2021	Mar 11, 2022	May 13, 2022	Aug 14, 2022	Nov 10, 2022	Feb 17, 2023	May 12, 2023	Aug 11, 2023	Nov 14, 2023	Mar 20, 2024	May 13, 2024	Aug 14, 2024	Nov 13, 2024	Mar 5, 2025	May 12, 2025	Aug 12, 2025	Nov 12, 2025	Mar 12, 2026	Mar 31, 2026	Aug 13, 2026
EPS Estimate	-0.95	-0.57	-0.46	-0.25	-0.16	-0.22	-0.28	-0.26	-0.36	-0.44	-0.32	-0.68	-0.71	-0.43	-0.77	-0.20	-	-0.02	0.09	0.08	0.01	-0.24	-0.25	-0.28	-0.65	-0.30	-0.25	-	-0.88	-0.20	-0.16	-0.12	-0.17	-0.14	-0.17	-0.17	-0.15	-0.13	-0.24	-0.28	-0.23	-0.27
EPS Actual	-0.50	-0.23	-0.28	-0.02	-0.43	-0.32	-0.69	-0.42	-0.67	0.50	0.24	-1.42	-0.61	-0.36	-0.33	-1.28	-0.34	-0.30	0.12	-0.18	0.02	-0.39	-0.31	-1.19	-0.47	-0.30	-0.14	-0.15	-0.32	-0.19	-0.02	-0.24	-0.06	-0.10	-0.14	-0.44	-0.09	-0.22	-0.05	-0.25	0.00	-0.27
Surprise	47.37%	59.65%	39.13%	92.00%	-168.75%	-45.45%	-146.43%	-61.54%	-86.11%	213.64%	175.00%	-108.82%	14.08%	16.28%	57.14%	-540.00%	-	-1400.00%	33.33%	-325.00%	100.00%	-62.50%	-24.00%	-325.00%	27.69%	0.00%	44.00%	-	63.64%	5.00%	87.50%	-100.00%	64.71%	28.57%	17.65%	-158.82%	40.00%	-69.23%	79.17%	10.71%	100.00%	0.00%
Timing	Pre-market	After-hours	After-hours	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	Pre-market	After-hours	After-hours	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	After-hours	Pre-market	After-hours	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	After-hours	Pre-market	Pre-market	Pre-market	-	Pre-market

Key Statistics & Ratios

Market Cap16.62B

Enterprise Value16.44B

Trailing P/E0.00

Forward P/E1111.11

Price / Sales26.83

Price / Book4.78

EPS-0.50

Book Value13.46

Revenue (TTM)619.48M

Gross Profit (TTM)283.54M

EBITDA-39.09M

Profit Margin-22.42%

Operating Margin-47.91%

Return on Equity-3.66%

Return on Assets-2.52%

Shares Outstanding270.70M

Shares Float182.12M

Beta-0.14

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%